Tuesday, Jun 21, 1988
South San Francisco, Calif. -- June 21, 1988 --The United States Patent Office today issues a patent for purified tissue plasminogen activator (t-PA). The patent is exclusively licensed to Genentech, Inc. "This is the first in a series of major patents that we expect to protect our pioneering work with tissue plasminogen activator," said Robert A. Swanson, chief executive officer.
The issuance of the patent is acknowledgment of the major scientific contribution made by Dr. Desire Collen and his coinventors at the Center for Thrombosis and Vascular Research at the University of Leuven, Belgium. The patent covers purified t-PA (known as a composition of matter patent) independent of the production process used to manufacture it. A counterpart patent has recently been officially allowed by the European Patent Office.
Genentech and its licenser, Innovi, N.V., today filed suit for patent infringement in the U.S. District Court for the District of Delaware against Wellcome Foundation, Ltd.; Wellcome Biotechnology, Ltd.; Burroughs Wellcome Co.; Genetics Institute, Inc.; Welgen Manufacturing, Inc.; GI Manufacturing, Inc. and BW Manufacturing, Inc.
Genentech's tissue plasminogen activator, trade named Activase®, was approved by the Food and Drug Administration in November 1987 for the treatment of heart attack victims. Today approximately 4,000 of the nation's 6,000 hospitals are stocking the product for emergency use in dissolving blood clots that cause heart attacks.Genentech is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceutical produced by recombinant DNA technology.
# # #